Abebe Kaleab Z, Scifres Christina, Simhan Hyagriv N, Day Nancy, Catalano Patrick, Bodnar Lisa M, Costacou Tina, Matthew Deanna, Illes Alexandra, Orris Steven, Duell Jessica, Ly Kathleen, Davis Esa M
Division of General Internal Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; Center for Clinical Trials & Data Coordination, Division of General Internal Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; Center for Research on Health Care, University of Pittsburgh, Pittsburgh, PA, USA.
Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of Oklahoma College of Medicine, Oklahoma City, OK, USA.
Contemp Clin Trials. 2017 Nov;62:43-49. doi: 10.1016/j.cct.2017.08.012. Epub 2017 Aug 18.
Gestational diabetes mellitus (GDM) affects approximately 5 to 7% of pregnancies and is associated with increased risk for fetal overgrowth, cesarean delivery, birth trauma, and pre-eclampsia. GDM is commonly diagnosed in the US using a two-step screening and confirmatory approach, whereas a one-step approach is commonly used outside the US. Recent guidelines have suggested that the one-step approach should be used to diagnose GDM, although concern that this may increase the prevalence of GDM to approximately 18%-as well as the lack of clinical trials-based evidence regarding the difference in perinatal outcomes-has led to skepticism about adopting the one-step approach. The Comparison of Two Screening Strategies for Gestational Diabetes (GDM) Trial is a single-center, parallel-arm, comparative effectiveness trial of one-step versus two-step GDM screening strategies on the rate of adverse perinatal outcomes including: large-for-gestational age (LGA) deliveries (primary outcome), small-for-gestational age (SGA), macrosomia, cesarean delivery, fetal growth and body composition, and maternal and neonatal composite outcomes. This paper describes the design and analysis plan of the GDM Trial as well as overall challenges in assessing the impact of screening and diagnosis strategy on adverse pregnancy outcomes. We will also assess whether the additional women diagnosed with the one-step approach benefit from treatment as assessed by metabolic profiles at one year postpartum. Ultimately, this study will provide the necessary evidence for establishing universal guidelines for GDM diagnosis and implementation into clinical care.
妊娠期糖尿病(GDM)影响约5%至7%的妊娠,与胎儿过度生长、剖宫产、产伤和子痫前期风险增加相关。在美国,GDM通常采用两步筛查和确诊方法进行诊断,而在美国以外地区通常采用一步法。最近的指南建议采用一步法诊断GDM,尽管担心这可能会使GDM的患病率增加到约18%,以及缺乏基于临床试验的围产期结局差异证据,导致人们对采用一步法持怀疑态度。妊娠期糖尿病(GDM)两种筛查策略比较试验是一项单中心、平行组、比较有效性试验,比较一步法与两步法GDM筛查策略对不良围产期结局发生率的影响,包括:大于胎龄(LGA)分娩(主要结局)、小于胎龄(SGA)、巨大儿、剖宫产、胎儿生长和身体组成,以及母婴综合结局。本文描述了GDM试验的设计和分析计划,以及评估筛查和诊断策略对不良妊娠结局影响的总体挑战。我们还将评估通过产后一年的代谢指标评估,采用一步法诊断出的额外女性是否从治疗中获益。最终,本研究将为制定GDM诊断通用指南并将其应用于临床护理提供必要证据。